Cargando…

RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome

Abnormal expression patterns of regulatory small non-coding RNA (sncRNA) molecules such as microRNAs (miRs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) play an important role in the development and progression of cancer. Identification of clinically relevant sncRNA signatures...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Gurvinder, Ruhela, Vivek, Rani, Lata, Gupta, Anubha, Sriram, Krishnamachari, Gogia, Ajay, Sharma, Atul, Kumar, Lalit, Gupta, Ritu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957689/
https://www.ncbi.nlm.nih.gov/pubmed/31932582
http://dx.doi.org/10.1038/s41408-019-0272-y
_version_ 1783487342456078336
author Kaur, Gurvinder
Ruhela, Vivek
Rani, Lata
Gupta, Anubha
Sriram, Krishnamachari
Gogia, Ajay
Sharma, Atul
Kumar, Lalit
Gupta, Ritu
author_facet Kaur, Gurvinder
Ruhela, Vivek
Rani, Lata
Gupta, Anubha
Sriram, Krishnamachari
Gogia, Ajay
Sharma, Atul
Kumar, Lalit
Gupta, Ritu
author_sort Kaur, Gurvinder
collection PubMed
description Abnormal expression patterns of regulatory small non-coding RNA (sncRNA) molecules such as microRNAs (miRs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) play an important role in the development and progression of cancer. Identification of clinically relevant sncRNA signatures could, therefore, be of tremendous translational value. In the present study, genome-wide small RNA sequencing identified a unique pattern of differential regulation of eight miRs in Chronic Lymphocytic Leukemia (CLL). Among these, three were up-regulated (miR-1295a, miR-155, miR-4524a) and five were down-regulated (miR-30a, miR-423, miR-486*, let-7e, and miR-744) in CLL. Altered expression of all these eight differentially expressed miRs (DEMs) was validated by RQ-PCR. Besides, seven novel sequences identified to have elevated expression levels in CLL turned out to be transfer RNA (tRNA)/piRNAs (piRNA-30799, piRNA-36225)/snoRNA (SNORD43) related. Multivariate analysis showed that miR-4524a (HR: 1.916, 95% CI: 1.080–3.4, p value: 0.026) and miR-744 (HR: 0.415, 95% CI: 0.224–0.769, p value: 0.005) were significantly associated with risk and time to first treatment. Further investigations could help establish the scope of integration of these DEM markers into risk stratification designs and prognostication approaches for CLL.
format Online
Article
Text
id pubmed-6957689
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69576892020-01-22 RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome Kaur, Gurvinder Ruhela, Vivek Rani, Lata Gupta, Anubha Sriram, Krishnamachari Gogia, Ajay Sharma, Atul Kumar, Lalit Gupta, Ritu Blood Cancer J Article Abnormal expression patterns of regulatory small non-coding RNA (sncRNA) molecules such as microRNAs (miRs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) play an important role in the development and progression of cancer. Identification of clinically relevant sncRNA signatures could, therefore, be of tremendous translational value. In the present study, genome-wide small RNA sequencing identified a unique pattern of differential regulation of eight miRs in Chronic Lymphocytic Leukemia (CLL). Among these, three were up-regulated (miR-1295a, miR-155, miR-4524a) and five were down-regulated (miR-30a, miR-423, miR-486*, let-7e, and miR-744) in CLL. Altered expression of all these eight differentially expressed miRs (DEMs) was validated by RQ-PCR. Besides, seven novel sequences identified to have elevated expression levels in CLL turned out to be transfer RNA (tRNA)/piRNAs (piRNA-30799, piRNA-36225)/snoRNA (SNORD43) related. Multivariate analysis showed that miR-4524a (HR: 1.916, 95% CI: 1.080–3.4, p value: 0.026) and miR-744 (HR: 0.415, 95% CI: 0.224–0.769, p value: 0.005) were significantly associated with risk and time to first treatment. Further investigations could help establish the scope of integration of these DEM markers into risk stratification designs and prognostication approaches for CLL. Nature Publishing Group UK 2020-01-13 /pmc/articles/PMC6957689/ /pubmed/31932582 http://dx.doi.org/10.1038/s41408-019-0272-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kaur, Gurvinder
Ruhela, Vivek
Rani, Lata
Gupta, Anubha
Sriram, Krishnamachari
Gogia, Ajay
Sharma, Atul
Kumar, Lalit
Gupta, Ritu
RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
title RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
title_full RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
title_fullStr RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
title_full_unstemmed RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
title_short RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
title_sort rna-seq profiling of deregulated mirs in cll and their impact on clinical outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957689/
https://www.ncbi.nlm.nih.gov/pubmed/31932582
http://dx.doi.org/10.1038/s41408-019-0272-y
work_keys_str_mv AT kaurgurvinder rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT ruhelavivek rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT ranilata rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT guptaanubha rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT sriramkrishnamachari rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT gogiaajay rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT sharmaatul rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT kumarlalit rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome
AT guptaritu rnaseqprofilingofderegulatedmirsincllandtheirimpactonclinicaloutcome